This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freeman, K. W. Articles by Spencer, D. M. Search for Related Content PubMed PubMed Citation Articles by Freeman, K. W. Articles by Spencer, D. M.

Conditional Activation of Fibroblast Growth Factor Receptor (FGFR) 1, but not FGFR2, in Prostate Cancer Cells Leads to Increased Osteopontin Induction, Extracellular Signal-regulated Kinase Activation, and in Vivo Proliferation¹

Departments of Immunology [K. W. F., R. D. G., D. M. S.], Cell and Molecular Biology [B. E. W., B. A. F., J. M. R., N. M. G.], and Pathology [M. O., M. I.], Baylor College of Medicine, Houston, Texas 77030

Changes in the fibroblast growth factor receptor (FGFR) axis are often associated with prostate cancer (CaP) progression. We have used chemically induced dimerization (CID) to elucidate the individual contributions of FGFR1 and FGFR2 to tumor etiology. Novel CaP cell lines stably expressing CID/AP20187-inducible FGFR1 (iFGFR1) and iFGFR2 were made using the tumorigenic transgenic adenocarcinoma of the murine prostate (TRAMP)-derived clone, TRAMP-C2N (C2N), to generate C2N.iFGFR1 or C2N.iFGFR2 cells. To test the effects of iFGFR activation on tumor growth, mice bearing s.c. C2N.iFGFR1- or C2N.iFGFR2-derived tumors were treated biweekly with CID. Activation of iFGFR1 led to rapid tumor growth as a result of increased proliferation. In contrast, expression of iFGFR2 inhibited tumor growth. Furthermore, we have ascertained that FGFR1 activation appears to be most important during the early stages of tumor development, but once established, tumors become rapidly CID independent. In these C2N-based lines, quantitative signaling differences were seen between the two receptors, with iFGFR1 leading to more robust extracellular signal-regulated kinase activation. Additionally, activation of iFGFR1, but not iFGFR2, led to strong up-regulation of osteopontin, a secreted glycoprotein involved in integrin activation and associated with CaP progression and metastasis. These studies support the hypothesis that observed changes in the FGFR axis in mammals during CaP progression are causally important.

This article has been cited by other articles:

				F. Yasuhara, G. R. O. Gomes, E. R. Siu, C. I. Suenaga, E. Marostica, C. S. Porto, and M. F. M. Lazari Effects of the Antiestrogen Fulvestrant (ICI 182,780) on Gene Expression of the Rat Efferent Ductules Biol Reprod, September 1, 2008; 79(3): 432 - 441. [Abstract] [Full Text] [PDF]

				Y. Deng, J. Yang, M. McCarty, and B. Su MEKK3 is required for endothelium function but is not essential for tumor growth and angiogenesis Am J Physiol Cell Physiol, October 1, 2007; 293(4): C1404 - C1411. [Abstract] [Full Text] [PDF]

				W. Xian, K. L. Schwertfeger, and J. M. Rosen Distinct Roles of Fibroblast Growth Factor Receptor 1 and 2 in Regulating Cell Survival and Epithelial-Mesenchymal Transition Mol. Endocrinol., April 1, 2007; 21(4): 987 - 1000. [Abstract] [Full Text] [PDF]

				Z. Q. Yang, K. L. Streicher, M. E. Ray, J. Abrams, and S. P. Ethier Multiple Interacting Oncogenes on the 8p11-p12 Amplicon in Human Breast Cancer Cancer Res., December 15, 2006; 66(24): 11632 - 11643. [Abstract] [Full Text] [PDF]

				L. Duchesne, B. Tissot, T. R. Rudd, A. Dell, and D. G. Fernig N-Glycosylation of Fibroblast Growth Factor Receptor 1 Regulates Ligand and Heparan Sulfate Co-receptor Binding J. Biol. Chem., September 15, 2006; 281(37): 27178 - 27189. [Abstract] [Full Text] [PDF]

				K. L. Schwertfeger, W. Xian, A. M. Kaplan, S. H. Burnett, D. A. Cohen, and J. M. Rosen A Critical Role for the Inflammatory Response in a Mouse Model of Preneoplastic Progression Cancer Res., June 1, 2006; 66(11): 5676 - 5685. [Abstract] [Full Text] [PDF]

				C. Zhong, G. Saribekyan, C.-P. Liao, M. B. Cohen, and P. Roy-Burman Cooperation between FGF8b Overexpression and PTEN Deficiency in Prostate Tumorigenesis Cancer Res., February 15, 2006; 66(4): 2188 - 2194. [Abstract] [Full Text] [PDF]

				J. Cheng, L. Yu, D. Zhang, Q. Huang, D. Spencer, and B. Su Dimerization through the Catalytic Domain Is Essential for MEKK2 Activation J. Biol. Chem., April 8, 2005; 280(14): 13477 - 13482. [Abstract] [Full Text] [PDF]

				G. Cario, M. Stanulla, B. M. Fine, O. Teuffel, N. v. Neuhoff, A. Schrauder, T. Flohr, B. W. Schafer, C. R. Bartram, K. Welte, et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia Blood, January 15, 2005; 105(2): 821 - 826. [Abstract] [Full Text] [PDF]

				B Kwabi-Addo, M Ozen, and M Ittmann The role of fibroblast growth factors and their receptors in prostate cancer Endocr. Relat. Cancer, December 1, 2004; 11(4): 709 - 724. [Abstract] [Full Text] [PDF]

				S. A. Shain Exogenous Fibroblast Growth Factors Maintain Viability, Promote Proliferation, and Suppress GADD45{alpha} and GAS6 Transcript Content of Prostate Cancer Cells Genetically Modified to Lack Endogenous FGF-2 Mol. Cancer Res., November 1, 2004; 2(11): 653 - 661. [Abstract] [Full Text] [PDF]

				C. Billottet, N. Elkhatib, J.-P. Thiery, and J. Jouanneau Targets of Fibroblast Growth Factor 1 (FGF-1) and FGF-2 Signaling Involved in the Invasive and Tumorigenic Behavior of Carcinoma Cells Mol. Biol. Cell, October 1, 2004; 15(10): 4725 - 4734. [Abstract] [Full Text] [PDF]

				K. W. Freeman, B. E. Welm, R. D. Gangula, J. M. Rosen, M. Ittmann, N. M. Greenberg, and D. M. Spencer Inducible Prostate Intraepithelial Neoplasia with Reversible Hyperplasia in Conditional FGFR1-Expressing Mice Cancer Res., December 1, 2003; 63(23): 8256 - 8263. [Abstract] [Full Text] [PDF]